Big news for academic medicine yesterday:

Dr. Brian Druker, CEO of the Knight Cancer Institute at Oregon Health & Science University and developer of a drug that revolutionized cancer treatment, said he was stepping down in part because OHSU had “forgotten our mission” and is no longer a place to do cutting-edge research.

The problem with academic medicine is that it is still part of American medicine, and an MD’s worth is measured in RVUs they can generate. This is easier to calculate and cross-compare with non-academic docs, so it wins out over any other activity in an MBA’s spreadsheet.